Setmelanotide Dosage, half-life & reference guide

Also known as Imcivree · RM-493 · BIM-22493

Reviewed 8 studiesEvidence: EstablishedPublished by PepVault

A daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant. In those people it cuts hunger and weight, by about 16% of BMI in a year in its 2026 hypothalamic-obesity trial, but the label says it is not expected to work in common obesity.

FDA label
0.5–3 mgstarting dose 0.5 mg
How often
Daily
Half-life
~11 hours
Evidence
●●● Established
Route
SubQ injection

Setmelanotide dose guide

How it works.

A melanocortin-4 (MC4) receptor agonist: an 8-amino-acid ring-shaped peptide built on α-MSH, the body's own signal on the brain's hunger and satiety pathway. Where that pathway is broken upstream of the MC4 receptor (a hypothalamic injury or tumour, Bardet-Biedl syndrome, or a POMC, PCSK1 or LEPR gene variant), it is thought to restore the signal, lowering hunger and food intake and raising energy use. It also acts, about 20-fold more weakly, on the MC1 receptor of pigment cells, which is why the skin darkens. FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026. The label says it is not expected to work in common (polygenic) obesity.

Commonly reported: Less hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020.

Half-life & active level

The half-life of Setmelanotide is ~11 hours (FDA label).

Here's how a typical Setmelanotide schedule accumulates over a week (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track setmelanotide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Setmelanotide works.

A body with Appetite & metabolism lit
  • Appetite & metabolism

    In people. In those people it cuts hunger and weight, by about 16% of BMI in a year in its 2026 hypothalamic-obesity trial.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
1–2 weeks (hunger)
Peak effect
52 weeks (BMI)
Duration
Ongoing
  1. Day 1–14 · 0.5 mgRCT

    The 0.5 mg start

    You're on 0.5 mg, the label's starting dose for hypothalamic obesity, for two weeks before the first step up. Commonly reported: some nausea and redness where the shot goes in while your body gets used to it.

    The science

    The Imcivree label starts adults and children 4 and older with acquired hypothalamic obesity at 0.5 mg once daily for 2 weeks and steps up if it is tolerated; in TRANSCEND the dose escalated to 1.5 to 3.0 mg before the 52-week treatment period (Miller 2026). Nausea was among its most common side effects there, with skin darkening, vomiting and headache.

    Sources
    • FDA Imcivree label (2026)
    • Miller et al. (TRANSCEND) (2026)

    Updated Nov 2026

  2. Day 1–14 · 2 mgClinical

    The 2 mg start

    You're on 2 mg, the label's starting dose for adults with Bardet-Biedl syndrome or a POMC, PCSK1 or LEPR variant, for two weeks before 3 mg. Commonly reported: nausea and injection-site redness early on, and hunger that starts to ease.

    The science

    The label starts adults and children 12 and older with BBS or POMC, PCSK1 or LEPR deficiency at 2 mg once daily for 2 weeks, then 3 mg; if 2 mg isn't tolerated it drops to 1 mg, and if 3 mg isn't, back to 2 mg. In Clément 2020, injection-site reactions were reported by every participant in both trials.

    Sources
    • FDA Imcivree label (2026)
    • Clément et al. (2020)

    Updated Nov 2026

  3. Day 14–90RCT

    Why the skin darkens

    Setmelanotide also touches the tanning receptor on pigment cells, so skin, freckles and moles usually darken, without sun. It fades after stopping, and the label calls for a skin check before starting and along the way.

    The science

    The label: generalised or focal skin darkening occurred in most trial patients, is reversible on stopping, and new or darker moles can appear, from MC1 receptor activation in melanocytes (about 20-fold weaker than at MC4) that builds melanin independently of UV light. In the BBS phase 3, skin hyperpigmentation was reported by 61% of patients (Haqq 2022).

    Sources
    • FDA Imcivree label (2026)
    • Haqq et al. (2022)

    Updated Nov 2026

  4. Day 15–365 · 3 mgRCT

    3 mg, the maintenance dose

    3 mg once a day is the label's maintenance dose for every approved use. In its year-long trials, hunger scores dropped and weight came down further over the months.

    The science

    In TRANSCEND (Miller 2026; 120 people with acquired hypothalamic obesity), BMI changed by -16.5% on setmelanotide vs +3.3% on placebo at 52 weeks, and the weekly maximal hunger score by -2.73 vs -1.45 points (0-10 scale). In Clément 2020, 8 of 10 people with POMC deficiency and 5 of 11 with LEPR deficiency lost at least 10% of their weight at about 1 year.

    Sources
    • Miller et al. (TRANSCEND) (2026)
    • Clément et al. (2020)

    Updated Nov 2026

  5. Any dayRCT

    What Setmelanotide is built on

    Setmelanotide is a precision drug: approved in 2020 for obesity from rare gene variants, with Bardet-Biedl syndrome and, in 2026, hypothalamic injury added. It works where the MC4 pathway is broken, and the label says it is not expected to work in common obesity.

    The science

    Approval rests on two single-arm phase 3 trials in POMC and LEPR deficiency (Clément 2020), a randomised phase 3 in BBS (Haqq 2022: 32.3% of patients 12 and older with BBS lost at least 10% of body weight at 52 weeks), a phase 2 (Roth 2024: BMI down 15% at 16 weeks) and the randomised phase 3 TRANSCEND in acquired hypothalamic obesity (Miller 2026). In 12 people with common obesity it raised resting energy use in the short term, but it is not approved for them (label).

    Sources
    • Clément et al. (2020)
    • Haqq et al. (2022)
    • Roth et al. (2024)
    • Miller et al. (TRANSCEND) (2026)

    Updated Nov 2026

  6. With Melanotan II and PT-141Clinical

    Setmelanotide, Melanotan II and PT-141 share receptors

    All three act on the melanocortin receptors, so their effects overlap rather than add up cleanly: skin darkening, nausea and sexual side effects run in the same family. Commonly reported: people who know Melanotan II recognise the tan and the nausea.

    The science

    Setmelanotide is an MC4 receptor agonist with weaker MC1 activity (Imcivree label). PT-141 (bremelanotide) is a melanocortin receptor agonist too, and its label also lists skin darkening with frequent use (Vyleesi label). No trial has combined them.

    Sources
    • FDA Imcivree label (2026)
    • FDA Vyleesi label (2026)

    Updated Nov 2026

Day 1 is the day you start it.

FDA Imcivree label (DailyMed, effective April 2026); Drugs@FDA approval history; TRANSCEND (Miller 2026); Roth 2024; Clément 2020; Haqq 2022. Approved only for obesity from acquired hypothalamic injury, BBS and POMC, PCSK1 or LEPR deficiency.

Clinical trial data

A typical run.

Run notes

Cycle
FDA-approved for long-term use ("reduce excess body weight and maintain weight reduction long term"); its trials ran 52 to 66 weeks. In the gene-variant trials, weight came back during a 4-week placebo withdrawal and fell again on restarting.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once daily at the beginning of the day, with or without food, in the abdomen, thigh or arm, rotating sites (label). A missed dose is skipped and the next one taken as scheduled. The vial comes out of the refrigerator about 15 minutes before the shot. Levels peak about 8 hours after a dose and reach a steady state within 2 days.
Route
SubQ injection

Track it in the app

Safety.

Common side effects

  • Skin darkening
  • Injection site reactions
  • Nausea
  • Headache
  • Diarrhea
  • Abdominal pain
  • Vomiting
  • Low mood
  • Spontaneous erections

Interactions

No clinical drug-interaction studies have been done; in lab tests setmelanotide showed a low potential for interactions through liver enzymes, transporters or protein binding (label). In hypothalamic obesity with diabetes insipidus, the label suggests watching sodium and adjusting the diabetes insipidus medicines as needed. It shares the melanocortin receptors with Melanotan II and PT-141. Discuss all your medicines with your clinician.

Safety notes

The Imcivree label has no boxed warning. Its warnings: spontaneous erections in men and sexual side effects in women (an erection lasting more than 4 hours needs emergency care); depression and suicidal thoughts, as with some other drugs that act in the brain, so mood is watched and a history of depression raises the risk; serious allergic reactions, including anaphylaxis; skin darkening in most trial patients, reversible after stopping, plus darker or new moles, so the label calls for a full-body skin check before starting and during treatment; in hypothalamic obesity, acute adrenal insufficiency (serious in 5% vs 0% on placebo) and, with central diabetes insipidus, low or high sodium. It is not recommended in end-stage kidney disease or while breastfeeding. These are label findings; review them with your clinician.

Brand-name products.

Questions people ask.

What is Setmelanotide?

A daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant. In those people it cuts hunger and weight, by about 16% of BMI in a year in its 2026 hypothalamic-obesity trial, but the label says it is not expected to work in common obesity.

How is Setmelanotide dosed in research?

The FDA label range for Setmelanotide is 0.5–3 mg, daily SubQ, with a 0.5 mg starting dose.

How long does Setmelanotide last?

The half-life of Setmelanotide is ~11 hours (FDA label).

What do people report on Setmelanotide?

Commonly reported on Setmelanotide: less hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020.

Is Setmelanotide safe?

The research basis for Setmelanotide is established: clinical trials or FDA-approved use exists. Common side effects in the library: skin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood and spontaneous erections.

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Daily

Daily SubQ

Half-life

~11 hours

~11 hours (FDA label)

Research basis

●●● Established

Clinical trials or FDA-approved use exists

PepVault for iPhone

Track setmelanotide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library